AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 261 min read$CTXR

Citius Pharmaceuticals: LYMPHIR Wholesaler Shipments Rise 120% in Fiscal Q4

Citius Pharmaceuticals reported a 120% increase in LYMPHIR units purchased by U.S. wholesalers in Q4 2026, rising from 360 to 792 units. Prescribing centers ordered 950 vials, up from 926 in Q3. The company aims to place LYMPHIR on formulary at 100 priority institutions by year-end. Full fiscal 2026 results are expected in December 2026, according to the company.

Original reporting
tradingview.com
Published Oct 26, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Citius Pharmaceuticals: LYMPHIR Wholesaler Shipments Rise 120% in Fiscal Q4 — source image
Source · tradingview.com
Decision brief

The 30-second read

$CTXRBullishMed
01

Why it matters

The 120% jump in wholesale units could boost short‑term sentiment but long‑term impact depends on formulary placement and pricing.

02

Market read

New sales data for a small‑cap biotech may move the stock modestly; sector peers could see spill‑over interest.

03

What to watch

The figures are preliminary and unaudited; actual revenue recognition may differ.

Relevance 6/10Novelty 6/10Timing: today

Background

Citius Pharmaceuticals' oncology subsidiary LYMPHIR is a niche cancer therapy; the company is awaiting broader formulary adoption.

Company-level read

Ticker impact

$CTXRBullishHigh confidence
Context

Citius Pharmaceuticals reported a 120% increase in LYMPHIR wholesale shipments to 792 units in Q4 2026, a new primary disclosure of sales growth.

Expected impact

upward pressure as the market prices in higher sales momentum

Evidence & confidence

First‑time reporting of Q4 shipment numbers shows a material improvement over the prior quarter, which traders typically view as a bullish catalyst.

Market effects

Sector

Positive signal for the oncology drug sector, indicating potential uptake of similar therapies.

Regional

U.S. biotech investors may view the data as a sign of demand recovery.

Global

Limited to niche oncology market; no broad macro impact.

Counterpoint

What could challenge this read

The shipment increase may be temporary if the product faces reimbursement hurdles or competition.

Key entities

  • company
    Citius Pharmaceuticals

    Biopharma developing LYMPHIR oncology therapy.

Read at source← All news

Related articles

OCT 26
$CTXRMed

Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of…

Citius Pharmaceuticals, Inc. (CTXR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 CRANFORD, N.J., October 26, 2026 - Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: C

SEC EDGAR 8-K2 min
AUG 14
$CTXRMed

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals (Nasdaq: CTXR) reported fiscal Q3 2026 results for the quarter ended June 30, 2026, and updated on LYMPHIR. Revenues were $1.5M for the quarter and $7.1M for nine months. Cash was $17.0M. LYMPHIR was available at 44 institutions, with expanded Citius Oncology teams and Phase 1 data presented. Citius Oncology (Nasdaq: CTOR) also reported progress and financing.

prnewswire.com7 min
AUG 14
$CTXRMed

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. (CTXR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update $7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2

SEC EDGAR 8-K6 min
MAY 24
$CTXRMedAI 8/10

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

H.C. Wainwright began coverage of Citius Pharmaceuticals (CTXR) on May 18 with a Buy rating and $4 price target, citing LYMPHIR’s approval for relapsed/refractory Stage I-III cutaneous T-cell lymphoma and encouraging early launch metrics. The report notes near-full commercial insurance coverage and initial Europe shipments via a regional partner. CTXR’s U.S. launch began in Dec. 2025.

finance.yahoo.com5 min